Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc GSK in a phase III ...

Moderna announced that its seasonal flu vaccine mRNA-1010 demonstrated 26.6% relative vaccine efficacy compared with standard approved flu vaccines in a phase 3 efficacy trial in adults aged 50 and up ...

Moderna’s seasonal influenza vaccine met its main goal in a large Phase 3 trial, reducing the risk of influenza-like illness in people 50 years and older by 27% compared with those given a marketed ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2. The data ...

Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed ...

The U.S. is in "big danger" of falling behind in vaccine technology research as government funding declines and vaccine ...

Oct 29 (Reuters) - Moderna Inc (MRNA.O), opens new tab on Thursday said it is on track to report early data from a late-stage trial of its experimental COVID-19 vaccine next month, offering the ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. CHICAGO — The Food and Drug Administration has granted ...

CHICAGO, Sept 17 (Reuters) - If Moderna Inc's (MRNA.O), opens new tab COVID-19 vaccine proves to be at least 70% effective, the company plans to seek emergency authorization for its use in high-risk ...

Parents might be able to vaccinate their kids as early as June. When a judge on Monday overruled the mask mandate on public transportation, parents with kids too young to be vaccinated felt renewed ...